A New Test May Spare Many Patients From an Unnecessary Burden

Medical progress often arrives quietly. It does not always appear as a dramatic breakthrough or a revolutionary machine. Sometimes it comes in the form of greater certainty, allowing patients to avoid treatments they may never have needed. In that space between science and relief, a new study is offering hope to many people facing breast cancer diagnoses.

Researchers have reported that millions of breast cancer patients could potentially avoid chemotherapy through the use of advanced genomic testing that identifies who is most likely to benefit from the treatment. The findings emerged from a large international clinical trial involving thousands of participants.

The study focused on patients with early-stage hormone-receptor-positive, HER2-negative breast cancer, one of the most common forms of the disease. Scientists used a genomic test called Prosigna, which analyzes the activity of genes linked to cancer recurrence.

Researchers found that more than two-thirds of participants could safely avoid chemotherapy without significantly affecting their cancer outcomes. Patients identified as low risk were treated primarily with hormone therapy rather than chemotherapy.

Five-year cancer-free survival rates remained remarkably similar between patients who received chemotherapy and those who did not. The results suggest that genetic profiling can help doctors make more personalized treatment decisions.

For many patients, avoiding chemotherapy may mean avoiding side effects such as fatigue, nausea, hair loss, fertility complications, and weakened immune function. Physicians involved in the research emphasized that chemotherapy remains essential for some individuals, but not necessarily for all.

The trial involved more than 4,000 participants from several countries, including the United Kingdom, Australia, New Zealand, Norway, Sweden, and Thailand. Researchers described the findings as an important step forward in precision medicine.

Experts say the study reflects a broader shift in cancer treatment toward tailoring therapies to individual biology rather than relying solely on traditional treatment pathways. Similar approaches have already begun transforming care in several oncology fields.

Researchers plan to continue monitoring long-term outcomes while exploring how genomic testing can become more accessible across healthcare systems worldwide.

AI-generated visuals are used for illustration and do not portray actual patients involved in the study.

Sources: The Guardian, American Society of Clinical Oncology, University College London, BBC, Citi Newsroom